Alkermes (ALKS) Cash & Equivalents (2010 - 2026)

Alkermes (ALKS) has reported Cash & Equivalents for 17 consecutive years, with $511.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 1.86% year-over-year to $511.5 million in Q2 2026; TTM through Jun 2026 was $511.5 million, a 1.86% decrease from a year earlier, with the FY2025 full-year figure at $388.6 million, up 33.46% from the prior year.
• Cash & Equivalents was $511.5 million for Q2 2026 at Alkermes, up from $351.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $665.8 million in Q2 2023 and troughed at $254.6 million in Q2 2022.
• A 5-year average of $423.2 million and a median of $398.0 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 161.46% in 2023 and plunged 38.82% in 2024, its largest moves.
• Over 5 years, Cash & Equivalents stood at $292.5 million in 2022, then soared by 56.41% to $457.5 million in 2023, then tumbled by 36.36% to $291.1 million in 2024, then surged by 33.46% to $388.6 million in 2025, then soared by 31.64% to $511.5 million in 2026.
• The last three Cash & Equivalents figures came in at $511.5 million (Q2 2026), $351.6 million (Q1 2026), and $388.6 million (Q4 2025), per Business Quant data.